Table IV.
Baseline clinical characteristics, RCC28, PC28 and ANC29 of patients with/without severe thrombocytopenia defined by >30 units of PC28.
| Variable | No severe thrombocytopenia (n=115) | Severe thrombocytopenia (n=28) | P-value |
|---|---|---|---|
| Age, years | 76 (52–94) | 74 (52–90) | 0.178 |
| Male/Female, n (%) | 79 (68.7)/36 (31.3) | 19 (67.9)/9 (32.1) | 1.000 |
| Hemoglobin level, g/dl | 8.1 (3.5–13.0) | 7.0 (5.5–10.2) | 0.004 |
| Platelet counts, ×109/l | 76.0 (14.0–1139.0) | 24.5 (2.0–270.0) | <0.001 |
| WBC, ×109/l | 2.5 (0.8–19.0) | 2.2 (0.8–24.4) | 0.344 |
| ANC, ×109/l | 1.1 (0.0–13.1) | 0.9 (0.1–19.6) | 0.692 |
| Blast in bone marrow, % | 6.8 (0.4–19.8) | 8.3 (0.3–18.4) | 0.557 |
| Cytogenetic risk according to IPSS-R, n (%) | 0.598 | ||
| Very good | 2 (1.7) | 0 (0.0) | |
| Good | 25 (21.7) | 9 (32.1) | |
| Intermediate | 27 (23.5) | 6 (21.4) | |
| Poor | 14 (12.2) | 1 (3.6) | |
| Very poor | 47 (40.9) | 12 (42.9) | |
| RCC28, units/month | 2 (0–14) | 8 (0–30) | <0.001 |
| PC28, units/month | 0 (0–30) | 60 (35–170) | <0.001 |
| ANC29, ×109/l | 0.5 (0.0–9.0) | 0.3 (0.0–9.3) | 0.039 |
| RDI-AZA1, % | 91 (68–97) | 81 (62–95) | 0.059 |
Data presented as median (range) unless otherwise shown. RDI-AZA1, relative dose intensity in the first cycle of azacitidine treatment; RCC, red cell concentrates; PC, platelet concentrate; ANC, absolute neutrophil counts; WBC, white blood cells.